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Emerging evidences show that changes in tumor stroma can adapt cancer cells to radiotherapy, thereby leading
to a reduction in tumor response to treatment. On the other hand, radiotherapy is associated with severe re-
actions in normal tissues which limit the amount radiation dose received by tumor. These challenges open a
window in radiobiology and radiation oncology to explore mechanisms for improving tumor response and also
alleviate side effects of radiotherapy. Transforming growth factor beta (TGF-β) is a well-known and multitasking
cytokine that regulates a wide range of reactions and interactions within tumor and normal tissues. Within tumor
microenvironment (TME), TGF-β is the most potent suppressor of immune system activity against cancer cells.
This effect is mediated through stimulation of CD4+ which differentiates to T regulatory cells (Tregs), in-
filtration of fibroblasts and differentiation into cancer associated fibroblasts (CAFs), and also polarization of
macrophages to M2 cells. These changes lead to suppression of cytotoxic CD8 + T lymphocytes (CTLs) and
natural killer (NK) cells to kill cancer cells. TGF-β also plays a key role in the angiogenesis, invasion and DNA
damage responses (DDR) in cancer cells. In normal tissues, TGF-β triggers the expression of a wide range of pro-
oxidant and pro-fibrosis genes, leading to fibrosis, genomic instability and some other side effects. These
properties of TGF-β make it a potential target to preserve normal tissues and sensitize tumor via its inhibition. In
the current review, we aim to explain the mechanisms of upregulation of TGF-β and its consequences in both
tumor and normal tissues.
1. Introduction
Tumor resistance is one of the main challenges of cancer therapy.
Resistance of tumor to radiotherapy increases the need for higher ra-
diation doses, which is associated with normal tissue toxicity [1]. In
fact, normal tissue injury is the main limiting factor for the delivery of
sufficient dose of ionizing radiation to tumor [2]. Although tumor
radiotherapy is associated with normal tissue injury, this should be
acceptable without causing severe damages to normal functions of or-
gans. This issue is even more critical for highly radiosensitive organs.
For example, radiotherapy of pelvis or chest cancers can affect the ac-
tivity of bone marrow stem cells, leading to a reduction of peripheral
blood cells, especially lymphocytes and platelets. Severe damages to the
bone marrow can attenuate immune system functions which lead to
infection and bleeding. This can cause severe side effects and may halt
the course of treatment [3]. Some other important side effects include
acute inflammation in the lung, heart, brain and gastrointestinal
system, which affect patients’ quality of life years after the end of
radiotherapy or even lead to death [4].
Minimizing normal tissue injury with efficient delivery of ionizing
radiation to tumor is a critical issue in radiotherapy [5]. Although some
technological advancements in recent decades have helped improve
localized radiotherapy, however, side effects to normal tissues and
tumor recurrence after radiotherapy remain critical problems [6]. The
knowledge of how normal tissues react to ionizing radiation can im-
prove the management of early and late side effects of radiotherapy.
Furthermore, the knowledge of tumor architecture as well as the cel-
lular and molecular mechanisms of tumor radioresistance can help us to
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suggest new approaches to increase response to radiotherapy and re-
duce probability of tumor recurrence [7].
Evidences show that ionizing radiation can change the normal level
of several factors such as cytokines in the body, which play a key role in
the progression of radiation-induced normal tissue injury [8]. Similar
effects have also been observed in tumor [9]. In fact, although ionizing
radiation kills cancer cells, responses from tumor microenvironment
(TME) to radiation and cell death adapt cancer and cancer stem cells to
subsequent doses of radiotherapy [7]. This causes reduction in the ef-
ficiency of radiotherapy while it amplifies normal tissue toxicity. One of
the most important factors that act in this way is transforming growth
factor (TGF)-β [10]. In the current paper, we aim to review the me-
chanisms of upregulation of TGF-β following exposure of cells to
radiotherapy. Furthermore, we explain cellular and molecular effects of
TGF-β in both tumor resistance to radiation and damage to normal
tissues.
1.1. TGF-β signaling
TGF-β includes three isoforms: TGF-β1, TGF-β2, TGF-β3, with three
types of receptors, TβR1, TβR2, and TβR3 [11]. It seems that TGF-β1
plays a central role in normal tissue injury and tumor resistance fol-
lowing radiotherapy. TGF-β inserts its effect through two known
pathways including canonical (Smad-dependent) and non-canonical
(Smad-independent) pathways [12].
1.2. Canonical pathway
After extracellular upregulation of TGF-β, it can bind to TβR2 or
TβR3. TβR3 can form a heteromeric complex with TβR2. TβR2 finally
interacts with TβR1 which is associated with activation of TβR1. The
activated TGF-β receptors trigger phosphorylation of Smad2 and Smad3
heterodimers. Smad2 and Smad3 in association with Smad4 develop a
complex that translocates into the nucleus and can regulate several
genes. Canonical pathway plays a central role in the regulation of fi-
brosis genes such as collagen I, collagen III, fibronectin, and α-SMA
[13].
1.3. Non-canonical pathway
Smad2/3 dependent pathways have potent interactions with other
signaling pathways that play key roles in the consequences of exposure
to external stimuli and activation of TGF-β signaling. However, TGF-β
interaction with its receptors can trigger regulation of non-Smad
pathways such as Rho/ROCK, p38, JNK etc. [14]. Stimulation of Rho/
ROCK pathway by TGF-β plays a key role in regulating the fibrosis
process [15]. Although TGF-β is known as an anti-inflammatory growth
factor, the interaction between TβR1 and TβR2 can induce upregulation
of TRAF4 and TRAF6, which trigger inflammatory mediators such as
NFκB, a multifunctional transcription factor [14]. NFκB can induce the
expression of COX-2, iNOS, STAT3 etc., which are involved in in-
flammation, fibrosis and EMT [16]. This pathway also has a potent
effect on apoptosis resistance of cancer cells [16]. TβR1/TβR2 also can
induce Ras and MAP3K7, result in upregulation of MAPKs, including
JNK p38, ERK. This pathway also can induce redox interactions, pro-
liferation and epithelial-to-mesenchymal transition (EMT), which cause
both damages to normal tissues and tumor resistance to therapy [15].
(Fig. 1)
1.4. Ionizing radiation triggers release of TGF-β
TGF-β is a multitasking cytokine that regulates proliferation, cell
death and management of immune system responses [17]. It is one of
the most common cytokines that is released following exposure of cells
to ionizing radiation. In contrast to some other cytokines, the release of
TGF-β has a direct relation with radiation dose [18]. This may indicate
that TGF-β is a critical marker of radiation toxicity and DNA damage in
irradiated cells. DNA damage, which is the first genetic consequence of
ionizing radiation in cells, leads to activation and upregulation of TGF-
βII [19]. It has been suggested that upregulation of both TGF-βI and
TGF-βII are involved in DNA damage responses (DDRs) in cells fol-
lowing exposure to clastogenic agents [20]. Furthermore, radiation-
induced cell death plays a key role in the release of TGF-β and sub-
sequent consequences. Radiation can kill cells through different me-
chanisms such as apoptosis, mitotic catastrophe, necrosis, senescence
and autophagy. Clearance of dying cells which undergo each of these
death mechanisms has different consequences. For example, apoptotic
bodies' clearance is done by macrophages, while necrotic cells release
damage-associated molecular patterns (DAMPs) to trigger lymphocytes.
Clearance of apoptosis by macrophages leads to the release of anti-in-
flammatory cytokines including TGF-β and IL-10. However, DAMPs can
trigger toll like receptors (TLRs) to upregulate NFκB and release in-
flammatory cytokines [21].
Based on the mentioned mechanisms, the balance between apop-
tosis and necrosis has a key role in the release of TGF-β. Some organs
and also some cancers such as bone marrow and its derived malig-
nancies such as lymphoma, have high incidence of apoptosis. By con-
trast, some tumors like sarcomas may not show apoptosis after radio-
therapy [22]. Another important factor that affects the incidence of
apoptosis and necrosis is radiation dose. Using low doses of radiation
can cause more apoptosis to necrosis ratio. This is obvious for doses of
radiation lower than 1 Gy. Hyperfractionated radiotherapy, which in-
volves some fractions per day, uses low radiation doses. However,
conventional and hypofractionated radiotherapy have higher doses per
fraction. The different consequences from each of these techniques may
be related to various types of cell death [23].
In addition to apoptosis, senescence is another major inducer of
TGF-β. Senescence of both normal and cancer cells have been shown to
trigger release of TGF-β [24,25]. Induction of DNA damage by ionizing
radiation leads to upregulation of DNA repair enzymes such as p53,
which may mediate senescence [26]. Furthermore, continuous ROS
generation following mitochondrial malfunction or overexpression of
NADPH oxidase enzymes plays a key role in the induction of senescence
following exposure to ionizing radiation [27,28]. (Fig. 2)
In addition to monocytes and macrophages, platelets are another
important source of TGF-β after radiotherapy. It has been confirmed
that platelets exist in association with other inflammatory cells within
fibrotic areas after exposure to ionizing radiation [29]. Platelets have a
large amount of TGF-β1 in comparison to other immune cells, which
play a central role in the development of radiation-induced fibrosis in
organs such as the heart [30]. Knockdown of platelet derived TGF-β1
has been shown to reduce fibrosis significantly [29].
1.5. TGF-β in normal tissues injury
TGF-β is a regulator of wound healing. However, its overproduction
after exposure to high doses of ionizing radiation can lead to severe
injuries in normal tissues. It is well documented that an increase in TGF-
β following exposure to ionizing radiation has a pivotal role in the
progression of several side effects in different organs [31]. Fibrosis is
the most common outcome following increase in TGF-β in normal tis-
sues. However, nowadays, it is well known that TGF-β can be involved
in some other mechanisms of normal tissue toxicity such as chronic
oxidative stress and second primary cancers, myelosuppresion and
heart failure [31]. In this section, we explain the mechanisms of TGF-β
induced normal tissue injury following exposure to ionizing radiation.
1.6. TGF-β in radiation-induced fibrosis
Fibrosis is an unusual stiffness of tissues, which results from ab-
normal deposition of collagen in extracellular matrix [32]. TGF-β plays
a pivotal role for progression of collagen and fibronectin deposition in
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extracellular matrix, leading to fibrosis. Studies have shown that TGF-β
can promote fibrosis through various signaling pathways. The canonical
pathway is mostly common known for promotion of fibrosis. However,
non-canonical TGF-β signaling pathways including mir-21, Rho/ROCK
and NADPH oxidase have a role in radiation-induced fibrosis [32].
1.7. Smad2/3 pathway
Smad2/3 is one of the most common signaling pathways that is
involved in progression of radiation-induced fibrosis [33]. Important
receptors of TGF-β including TβRI and TβRII enhance the expressions of
Smad2 and Smad3. Knockdown of Smad3 has confirmed that TGF-β
potentiates radiation fibrosis through this pathway [34]. Upregulation
of Smad2/3 during the process of fibrosis, increase in the expressions of
collagen I and III, vimentin and α-SMA following exposure to radiation,
have been confirmed by several studies (Dai et al., 2019; [35,36]). It
seems that upregulating some other mediators such as miR-21 and
mTOR2 is involved in the induction of fibrosis through activation of Akt
and Smad2/3 [37,38]. Targeting mTOR2 has shown that attenuate the
expression of α-SMA and collagen in the lung. mTOR2 also help to
progression of fibrosis via suppression of apoptosis in fibroblasts (Dai
et al., 2019). MiR-21 is able to suppress Smad7, an inhibitor of Smad3
[39].
1.8. Rho/ROCK pathway
This pathway is involved in several functions including cytoskeleton
and cell polarity [40]. This pathway plays a key role in wound healing
[41]. The involvement of Rho/Rock pathway in the progression of fi-
brosis have been confirmed by some studies [42]. This pathway is
known as a regulator of radiation-induced fibrosis following upregu-
lation of TGF-β. Thus, targeting this pathway has been suggested for
reducing side effects of radiotherapy. For the first time, it has been
shown that Rho/Rock plays a key role in late fibrosis of the lung and
heart tissues following irradiation [43]. Suppression of this pathway
after irradiation has been shown to reduce the connective tissue growth
factor (CTGF) and fibrogenesis process in intestinal cells [44]. This
pathway also triggers the binding of NFκB to DNA [44]. Upregulation
Fig. 1. TGF-β signaling including canonical and non-canonical pathways.
Fig. 2. Mechanisms of radiation-induced TGF-β activation. DNA damage can
lead to cell death through different mechanisms. Among them, apoptosis and
senescence are responsible to induce macrophages to release TGF-β.
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and nuclear translocation of NFκB may further amplify fibrogenesis
through stimulation of EMT and the expression of some pro-fibrosis
genes such as COX-2 and other inflammatory mediators [45].
Inhibition of Rho pathway can attenuate the activities of fibroblasts
[46]. Pravastatin is a drug that can inhibit Rho/Rock pathway. Using
pravastatin has been shown to suppress EMT and upregulation of type I
collagen and fibronectin following irradiation of rat’s intestine. Pra-
vastatin could suppress both inflammation and fibrosis in rat’s intestine,
thereby indicating the role of Rho/Rock pathway in the stimulation of
both inflammatory and fibrotic processes [47]. A clinical trial con-
firmed that pravastatin ameliorates skin fibrosis in patients that un-
derwent radiotherapy for head and neck cancers [48]. Selective in-
hibition of Rho shows that this pathway may be involved in the side
effects of ionizing radiation through attenuation of DDR. A study
showed that inhibition of Rho can enhance DNA repair capacity, thus
reduces apoptosis. This was also associated with alleviation of lung fi-
brosis after irradiation [49].
1.9. NOXs pathway
Radiation-induced fibroblast senescence plays a key role in the ac-
tivation of fibroblasts and fibrosis [50]. Senescence is a key regulator of
fibrosis through activation of TGF-β–NOXs pathway. It has been ob-
served that senescence caused by ionizing radiation-induced activation
of NOX4 can also further activate TGF-β receptors I&II, leading to fi-
brosis through activation of canonical pathway [51]. ROS generation by
NOX enzymes plays a key role in the upregulation of TGF-β and pro-
gression of radiation-induced fibrosis. Attenuation of NOX4 expression
and also administration of antioxidants has been shown to reduce the
expression of TGF-β and accumulation of extracellular matrix collagen
[52].
1.10. MiR-21
MiR-21 is a critical regulator of several reactions in normal and
cancer cells to ionizing radiation. In normal tissues, it can suppress
antioxidant defense and also amplify fibrosis after radiotherapy. MiR-
21 can be induced following upregulation of TGF-β [53]. However,
overexpression of MiR-21 can increase the regulation of TGF-β fol-
lowing suppression of SOD2 and increase in oxidative stress. MiR-21 is
able to potentiate TGF-β signaling, leading to enhancing fibrosis de-
velopment [54]. Induction of MiR-21 after irradiation induces the up-
regulation of TGF-β–Smad2, while it reduces the expression of Smad7.
Inhibition of MiR-21 could reverse this pathway and attenuate radia-
tion-induced pulmonary fibrosis [54]. (Fig. 3)
1.11. TGF-β in chronic oxidative stress and genomic instability
Continuous production of ROS/NO is a common consequence of
exposure to ionizing radiation in various cells/organs. Although io-
nizing radiation induces its detrimental effect mainly through produc-
tion of ROS, changes in reduction/oxidation (redox) reactions after
exposure to radiation play a key role in oxidative stress, genomic in-
stability, carcinogenesis, inflammation and other side effects of ionizing
radiation [55]. To date, several ROS sources have been known within
cells. NADPH oxidases (NOXs) and dual oxidases (DUOXs), COX-2, in-
ducible nitric oxide synthase (iNOS), lipoxygenases (LOX), endoplasmic
reticulum, and mitochondria can generate free radicals during normal
or pathological conditions [56]. Interestingly, most of these mediators
are highly dependent on TGF-β level and the expression of its receptors
[57]. These enzymes and organelles act in a positive feedback loop with
each other, hence, increased ROS generation by one of these mediators
can induce the expression and activity of the other [55].
1.12. TGF-β–NOXs pathways
NOX enzymes are potent ROS generating enzymes. NOX2, NOX4
and NOX5 are important sources of H2O2, which are mainly regulated
by innate immune system. However, some non-immune cells such as
epithelial and bronchial cells in the lung are able to express some NOX
enzymes [58]. These enzymes can be upregulated following apoptosis
and senescence. These types of cell death are frequent in highly
radiosensitive organs like bone marrow and intestine [59]. However,
some others such as lung and brain have shown high incidence of se-
nescence and upregulation of some subfamilies of NOXs [60]. In bone
marrow, ionizing radiation causes death of progenitor and growing
hematopoietic cells, mainly through apoptosis. After exposure to io-
nizing radiation, an increase in the level of TGF-β is observed in the
bone marrow. Inhibition of TGF-β1 in mice following whole body ir-
radiation has been shown to reduce the expressions of NOX2 and NOX4,
leading to a reduction in oxidative stress and death of stem and pro-
genitor cells [61].
1.13. TGF-β−COX-2 pathway
COX-2 is responsible for metabolism of prostaglandins. ROS is one
of the second metabolites of this metabolism. TGF-β can augment the
expression of COX-2 through non-canonical pathway. However, it has
been confirmed that TGF-βRI can also induce COX-2 through canonical
pathway [62]. Inhibition of COX-2 has been shown to reduce radiation
injury in some tissues and organs such as joints, lung, bone marrow and
skin [63]. The potent induction effect of TGF-β on COX-2 gene ex-
pression has been confirmed in bystander studies. This phenomenon
will be discussed.
1.14. TGF-β–iNOS pathway
NO sources within tissues include some nitric oxide synthase (NOS)
enzymes such as iNOS, neuronal nitric oxide synthase (nNOS) and en-
dothelial nitric oxide synthase (eNOS) [64]. Among them, nNOS pro-
tects vessels against ROS. Low level of NO compared to ROS is re-
sponsible for vascular injury following exposure to ionizing radiation
[65]. By contrast, upregulation of iNOS can augment oxidative stress
and amplify toxic consequences of ionizing radiation. Although many
types of cells are able to synthesize iNOS, it seems that activated
macrophages are the main sources of NO following exposure to ionizing
radiation. TGF-β is a potent inducer of iNOS. It has been confirmed that
TGF-βRI–iNOS pathway plays a key role in NO production following
exposure to ionizing radiation [66]. TGF-βRI–iNOS pathway plays a key
role in bystander effect, which will be discussed.
1.15. TGF-β in radiation-induced bystander effect
Bystander effect is a phenomenon that causes the release of a wide
range of agents from irradiated cells to induce some changes in other
cells. As a result, bystander effect can augment radiation toxicity [67].
Irradiated cells amplify detrimental consequences of exposure to io-
nizing radiation via the release of several cytokines, microRNAs, nitric
oxide (NO), exosomes etc. [68]. It seems that changes in the expressions
of some ROS generating enzymes, mitochondria malfunction and
changes in the methylation of some critical genes, play a key role in the
bystander effect [67]. In vitro and in vivo studies have confirmed the
role of TGF-β in oxidative stress and genomic instability in bystander
cells/tissues. TGF-β can be released from macrophages following
apoptosis or senescence of irradiated cells and then migrates and affect
other areas. TGF-β can trigger macrophages to upregulate inducible
nitric oxide synthase (iNOS), which lead to production of NO [66].
Inhibition of TGF-βRI can reduce the generation of NO in bystander
cells. Furthermore, produced NO from direct irradiated cells can mi-
grate to adjacent cells and attack the DNA [66]. NO can also interact
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with generated superoxide (O2) and hydrogen peroxidase (H2O2) from
the mitochondria, leading to the production of higher half-life perox-
ynitrite free radicals.
One of the most important inducers of oxidative stress after ex-
posure to radiation is upregulation or downregulation of epigenetic
modulators. The role of epigenetic modulators such as miRNAs and
siRNAs, and also changes in the global and promoter DNA methylation
have been confirmed [67]. Some studies suggested that TGF-β can in-
duce oxidative stress through upregulation of mir-21. In vitro evalua-
tion of bystander mechanisms showed that MiR-21 can suppress activity
of superoxide dismutase 2 (SOD2), leading to increased superoxide to
antioxidant defense ratio [69]. Further studies showed that TGF-β is the
most important stimulator of MiR-21 in bystander cells [70]. Usually,
TNF-α can increase the activity of SOD2 and SOD3. However, it seems
that in bystander cells, high expression of TGF-β receptors can suppress
SOD2 and increase ROS level through TGF-β-mir-21-ROS pathway [53].
By contrast to MiR-21, MiR-663, an inhibitor of TGF-β, can reduce DNA
damage and micronuclei formation in bystander cells. Interestingly, it
has been shown that upregulation of TGF-βI in bystander cells results
from suppression of MiR-663 following exposure of cells to ionizing
radiation [71].
In vivo studies have shown that TGF-β can affect gene expression
and oxidative stress in distant non-irradiated tissues. It has been shown
that TGF-β upregulates the expression of COX-2 in lung tissues fol-
lowing local irradiation of the abdomen. Upregulation of COX-2 occurs
following the expression of TGF-βRI and upregulation of both canonical
and non-canonical signaling pathways [72]. Increased expression of
TGF-βRI−COX-2 can increase ROS production, leading to mutations
and oxidative injury in the DNA [73]. The upregulation of TGF-
βRI−COX-2 has also been shown for heavy charged radiation particles
[74]. As earlier mentioned, TGF-β can also increase the expression of
NADPH oxidase enzymes. The significant increase in the expression of
NOX2 and NOX4 subfamilies of NADPH oxidase have been observed for
lung tissues following local irradiation of the pelvis [75].
It has been suggested that TGF-βRI–Smad2 pathway plays a critical
role in the stimulation of micronuclei formation in bystander fibroblasts
cells. Inhibition of TGF-βRI leads to suppression of micronuclei for-
mation (a marker of DNA damage and probably ROS generation) in
bystander fibroblast cells (Yin et al., 2015b). (Fig. 4) (Table 1)
1.16. TGF-β in tumor resistance to radiotherapy
Cancer cells and cancer stem cells (CSCs) are surrounded by im-
mune system cells such as macrophages (including M1 and M2 types),
dendritic cells, neutrophils, cancer associated fibroblasts (CAFs), T
regulatory cells (Tregs) and cytotoxic CD8 + T lymphocytes (CTLs)
[76]. The immune cells have several interactions that regulate sup-
pression or progression of cancer cells’ proliferation, stemness of CSCs,
angiogenesis and finally tumor growth. TGF-β is one of the most im-
portant regulators of tumor growth via regulation of several functions
within the tumor [77]. Although TGF-β may have a suppressive effect
in the proliferation of cancer cells in grade I tumors, it can suppress
immune activation and facilitate immune escape of cancer cells [11].
The expression of TGF-β has a direct relation with tumor grade, which
indicates its critical role in tumor growth [78]. Radiation is a potent
inducer of TGF-β within TME. Although radiation kills cancer cells
through different mechanisms, dying cells trigger the release of several
cytokines including TGF-β to promote cancer progression and reverse
depletion of cells after radiotherapy [11]. In this section, we explain the
cellular and molecular mechanisms of TGF-β role in tumor resistance to
radiotherapy.
Fig. 3. Mechanisms of TGF-β induced fibrosis in irradiated organs. Apoptosis and senescence are the main causes of fibrosis following exposure to high doses of
ionizing radiation. Both types of cell death mechanisms are able to trigger fibrosis through stimulation of canonical and non-canonical signaling pathways.
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1.17. TGF-β suppresses immune system and facilitates cancer immune
escape
The balance between pro-tumor and anti-tumor immune cells plays
a key role in the fate of cancer therapy. CTLs, M1 macrophages and NK
cells are the most important anti-cancer cells within TME. On the other
hand, Tregs, CAFs and M2 macrophages increase proliferation and
viability of cancer cells and CSCs [76]. TGF-β plays a central role in the
regulation of cancer and CSCs proliferation and suppression of anti-
cancer cells including CTLs and NK cells [11]. CAFs are the main source
of TGF-β within TME. However, Tregs plays a key role in suppression of
CTLs and NK cells via release of TGF-β. Release of TGF-β also shifts
polarization of macrophages to M2 type. The positive feedbacks be-
tween these cells potentiate proliferation of cancer cells and promote
stemness of CSCs [76].
As mentioned earlier, ionizing radiation can kill cancer cells
through different mechanisms. Immunogenic cell death triggers lym-
phocytes to release inflammatory cytokines such as IFN-γ and TNF-α to
kill cancer cells [76]. However, overexpression of some inflammatory
mediators like NFκB can increase survival of cancer cells via induction
of anti-apoptotic genes [16]. Thus, inflammatory responses may be in
favor of elimination of cancer cells. Tolerogenic cell death including
apoptosis and senescence trigger the release of TGF-β and IL-10, which
suppress inflammation within TME. Apoptosis to necrosis/necroptosis
ratio is highly dependent on tumor type and dose of ionizing radiation.
In some cancers such as bone marrow derived malignancies, apoptosis
is the most common type of death in irradiated cells [23]. TGF-β can
suppress inflammatory responses and immune activity against cancer
cells through different mechanisms. TGF-β inhibits the release of IL-2 to
prevent proliferation of CTLs and NK cells [11]. TGF-β also facilitates
proliferation of CD4+ to Tregs and fibroblasts to CAFs. It also shifts
differentiation of macrophages into M2 cells. These cells trigger further
release of anti-inflammatory cytokines including TGF-β, IL-4 and IL-13,
which are associated with further suppression of CTLs and NK cells.
TGF-β through this way inhibits secretion of anti-cancer cytokines in-
cluding IFN-γ and TNF-α [76]. Thus, inhibition of TGF-β can be
suggested for reducing exhaustion of immune system and to reverse
infiltration of tumor promoting cells. TGF-β suppression in combination
with radiotherapy has also been shown to increase the numbers of CTLs
and NK cells within tumor [10].
Immune checkpoints are important targets that are interesting for
immunotherapy. Targeting immune checkpoints with immune check-
point inhibitors (ICIs) in combination with radiotherapy has shown
promising results [76]. PD-1 and CTLA-4 are two common immune
checkpoints that are used to enhance immune activity against cancer
progression. These proteins mediate apoptosis of CD4+, CTLs and DCs,
thus reduce immune system’s activity within TME [79]. Unfortunately,
the sensitivities of these cells are higher compared to Tregs and CAFs.
This leads to higher ratio of tumor promoting cancer cells compared to
anti-tumor cells. Reversing this ratio is critical for increasing tumor
response to radiotherapy [76]. TGF-β plays a key role in the regulation
of PD-1 and CTLA-4, thus promotes apoptosis in CTLs and DCs [80].
TGF-β has a key role in the regulation of T cell receptor (TCR) activa-
tion, which lead to upregulation of PD-1 and induction of apoptosis in
CD8+ cytotoxic lymphocytes [81]. Proliferation of Tregs by TGF-β can
also increase the production of both PD-1 and CTLA-4 within TME [82].
(Fig. 5)
1.18. TGF-β in DNA damage response (DDR) in cancer cells
TGF-β has a close relation with DDR and adaptation to clastogenic
agents such as ionizing radiation [83]. It seems that TGF-β has a role in
phosphorylation of DNA repair enzymes. Thus, targeting of TGF-β has
been proposed for induction of apoptosis and increasing the therapeutic
efficiencies of a wide range of anti-cancer modalities. Suppression of
TGF-β has been shown to reduce phosphorylation of H2AX, ATM and
p53, critical enzymes for initiation of DDR following exposure to ra-
diation [83]. As TGF-β has a multi-effect cytokine, it may have different
effects on various types of cancer in this way. Treatment of human
nasopharyngeal carcinoma CNE-2 cell with TGF-β has been shown to
induce apoptosis, while activation of Smad3, a downstream of TGF-β
increases cell resistance [84]. However, it has been confirmed that it
Fig. 4. Mechanisms of TGF-β induced oxida-
tive stress in directly irradiated and bystander
cells/tissues. TGF-β can induce ROS/NO gen-
eration in both immune and non-immune cells.
Upregulation of COX-2, iNOS, NOX2&4, and
also mitochondrial malfunction are main rea-
sons for chronic oxidative stress in both direct
irradiated and bystander cells/organs.
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increases resistance of a wide range of cancers. Molecular analyses
show that TGF-β inhibits regulation of miR-182, which itself causes
suppression of BRCA1 and forkhead box O3 (FOXO3). Thus, suppres-
sion of TGF-β can downregulate FOXO3 and BRCA1, thereby preventing
phosphorylation of ATM and attenuation of the homologous re-
combination (HR) repair pathway [85]. Attenuation of these enzymes
following suppression of TGF-β has been shown to reduce resistance of
cancer cells to ionizing radiation [86]. In the absence of activated ATM
and HR, cells use other alternative DNA repair pathways that are error
prone and higher cell death probability [85]. (Fig. 6)
1.19. TGF-β interactions with hypoxia and angiogenesis during
radiotherapy
Angiogenesis is the formation of new vessels, which is a common
mechanism during growth of embryo and also tissues in adults.
Angiogenesis in tumors is a critical demand for tumor growth [87]. In
fact, tumors progress faster than their vessels, however, this causes
chronic hypoxia and limits sufficient supply of nutrients for cancer cells
[88]. Insufficient nutrient can change the metabolism of cancer cells,
however, hypoxia can trigger angiogenesis through stimulation of some
genes such as HIF-1 and VEGF [89]. Hypoxia is a potent inducer of TGF-
β. Hypoxia regulates macrophages to M2 type cells, which are a source
of TGF-β [11]. Furthermore, CAFs within hypoxia condition release
TGF-β to promote angiogenesis [11]. In irradiated glioma, it has been
shown that hypoxia induces homing hematopoietic stem cells towards
tumor via TGF-β-HIF-1 pathway [90]. Irradiation of cancer cells has
been shown to increase the release of TGF-β and the expressions of TGF-
βI and TGF-βII [91]. There are limited studies on the interactions be-
tween angiogenesis and TGF-β in irradiated tumor or cancer cells.
These interactions lead to tumor resistance through several mechan-
isms. (Fig. 6) Blockade of TGF-βI has been shown to reduce microvessel
density in irradiated glioblastoma [92]. Although it has been observed
that inhibition of TGF-β can sensitize cancer cells to ionizing radiation
and suppress tumor growth [34,93], the exact interactions between
TGF-β and angiogenesis factors during radiotherapy need to be eluci-
dated.
1.20. TGF-β targeting and EMT in radiotherapy
EMT within TME is a process in which the epithelial cells undergo
some genetic changes to become mesenchymal stem cells. These new
cells have ability to undergo differentiation to various types of cells.
EMT and also polarization of mesenchymal cells to other types of cells is
highly dependent on releases and interactions within TME. It has been
shown that irradiation can induce EMT and stemness of cancer cells,
which leads to radioresistance of cancer cells [94]. However, inhibition
of TGF-βRI can reverse radioresistance of irradiated cells [91]. TGF-β
plays a key role in EMT and also polarization of mesenchymal cells to
tumor promoting cells such as CAFs [95]. Radiation-induced EMT is
also mediated through polarization of macrophages into M2 cells, a
process which is mediated by TGF-β signaling [96]. In A549 cells, up-
regulation of MiR-3591-5p plays a key role in the activation of TGF-β-
Smad2/3 pathways and EMT following irradiation. Inhibition of this
pathway has also been shown to suppress phosphorylation of Smad2/3
and EMT [36]. Similar results have been reported for lung cancer xer-
ografts [97].
1.21. Clinical trials for TGF-β blockade in combination with radiotherapy
Due to several positive results from experimental studies, some
clinical studies have been designed to use TGF-β antagonists for cancer
patients undergoing radiotherapy. In the first published clinical study,
patients with metastatic breast cancer were treated with TGF-β
blocking antibody fresolimumab and received focal radiotherapy to
metastatic sites. Results showed interesting increase in overall survival,Ta
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which was associated with increased numbers of peripheral CD8 + T
cells [98]. Results of this study confirmed experimental outcomes of
TGF-β inhibition in tumor, which can boost immune system against
cancer. (Table 2)
Some other clinical trials are ongoing and are close to completion.
Another clinical trial has attempted to use anti-TGF-β LY2157299 for
metastatic breast cancer patients (NCT02538471). Fresolimumab as
anti-TGF-βI is also being used in combination with stereotactic ablative
radiotherapy (SAR) for patients with non-small cell lung cancer
(NCT02581787). A study of LY2157299 combination with radiation
and chemotherapy with Temozolomide for patients with grade 3–4
glioma tumors has been completed (LY2157299) and another trial for
rectal cancer patients is ongoing (NCT02688712).
2. Conclusion
As mentioned in this paper, TGF-β plays a key role in radiotherapy
outcomes. Due to the critical role of TGF-β in both tumor resistance and
normal tissue injury, it affects therapeutic efficiency potently. Fibrosis
is probably the most common effect of TGF-β in normal tissues. Fibrosis
is a very important side effect of radiotherapy that may affect patients’
quality of life or could lead to death. TGF-β triggers the deposition of
collagen and fibronectin through various signaling pathways including
Rho/Rock, Smad2/3, NADPH oxidase, COX-2, epigenetic modifications
and also hormone changes including renin-angiotensin system. TGF-β
also stimulates the activities and regulation of some pro-oxidant en-
zymes including iNOS and especially NOX2 and NOX4, which lead to
continuous production of free radicals. It has been confirmed that these
changes are associated with genomic instability, which is a hallmark of
carcinogenesis.
TGF-β in TME is the most potent suppressor of immune system’s
activity against cancer cells. TGF-β can directly promote cancer cells’
proliferation. Furthermore, it induces proliferation of Tregs and CAFs,
which are sources of TGF-β in TME. The positive feedback between
TGF-β, Tregs and CAFs suppresses proliferation of CD8 + T cells and
NK cells. Furthermore, TGF-β inhibits the release of anti-cancer cyto-
kines such as IFN-γ and TNF-α from CD8 + T cells. Stimulation of DDR
in response to radiotherapy also increases resistance of cancer cells.
TGF-β can trigger angiogenesis and metastasis via stimulation of EMT
and HIF-1. Targeting of TGF-β in experimental studies has shown pro-
mising results for both normal tissues and tumor. The combination of
anti-TGF-β drugs with radiotherapy may enhance tumor response and
Fig. 5. Mechanisms of TGF-β induced immune
system suppression and immune escape of
cancer (stem) cells. TGF-β induces infiltration
of monocytes and polarization into M2 type of
macrophages. On the other hand, TGF-β plays
a key role in the polarization of fibroblasts into
CAFs and CD4 + T cells into Tregs. These cells
are able to potentiate each other through a
positive feedback loop. TGF-β is a key mediator
of this positive feedback.
Fig. 6. TGF-β-induced tumor resistance following radio-
therapy. Apoptosis and senescence after radiotherapy trigger
release of TGF-β by macrophages. However, hypoxia can
further amplify release of it. TGF-β can increase tumor re-
sistance to radiotherapy through various mechanisms in-
cluding stimulation of DDR, EMT, and angiogenesis.
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also reduce side effects.
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